Ann Lab Med 2018; 38(5): 446-449  
Asymmetrical Dimethylarginine Levels in Hepatitis B Virus-Positive Patients
Faruk Karakecili, M.D.1, Aytekin Cikman, M.D.2, Merve Aydin, Ph.D.2,3, and Baris Gulhan, M.D.2
Departments of Infectious Diseases and Clinical Microbiology1 and Medical Microbiology2, Erzincan University Faculty of Medicine, Erzincan, Turkey; Department of Medical Microbiology3, KTO Karatay University Faculty of Medicine, Konya, Turkey
Corresponding author: Faruk Karakecili
https://orcid.org/0000-0002-7368-7187
Departments of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan University, Erzincan 24030, Turkey
Tel: +90-532-3331706
Fax: +90-446-2261819
E-mail: drfarukkarakecili@hotmail.com
Received: May 26, 2017; Revised: May 26, 2017; Accepted: May 3, 2018; Published online: September 1, 2018.
© Korean Society for Laboratory Medicine. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: High asymmetrical dimethylarginine (ADMA) levels have been associated with endothelial dysfunction and contribute to the development of several diseases. However, data on the relationship between hepatitis B virus (HBV) and ADMA are limited. The aim of our study was to explore the relationship between ADMA and HBV by comparing the ADMA levels in patients with chronic active hepatitis B (CHB), inactive HBV carriers (carriers), and healthy volunteers (controls).
Methods: The participants were divided into three groups: 90 patients with CHB, 90 HBV carriers, and 90 controls. Serum ADMA levels were quantified using an ELISA kit (Cusabio, Wuhan, China). The data were analyzed using an ANOVA or the Kruskal-Wallis test as appropriate, with P<0.05 considered significant.
Results: Serum ADMA levels were significantly higher in patients with CHB (228.35±91.10 ng/mL) than in HBV carriers (207.80±75.80 ng/mL) and controls (207.61±89.10 ng/mL) (P=0.049). The clinical scores of the patients were positively correlated with ADMA levels.
Conclusions: The elevated serum ADMA levels in patients with CHB confirm that HBV plays a role in vasculitis. Further investigation of the mechanisms contributing to the high levels of ADMA in CHB may contribute toward development of new treatment modalities.
Keywords: Asymmetric dimethylarginine, Hepatitis B virus, Chronic active hepatitis B, Inactive hepatitis B virus carrier



This Article

e-submission

Archives

Indexed/Covered by